

Dear [YOUR_REPRESENTATIVE'S_NAME] ,

I am writing to express my concerns about the ongoing shortage of GLP-1 drugs, which are essential for my treatment of obesity. Currently, I rely on prescribed compounded tirzepatide to ensure I can consistently fill my prescription. This alternative has been vital in maintaining my treatment regimen, as it allows me to access the medication without interruption, unlike relying on sourcing the branded Zepbound (tirzepatide) medication which caused disruptions in my treatment regimen.

Moreover, the compounded version has significantly reduced my monthly expenses, bringing the cost down from \$1,200 to \$400. This affordability is crucial for my continued treatment and overall health.

I am also deeply concerned about Eli Lilly's recent statement to have Zepbound (tirzepatide) removed from the FDA shortage list.^[1] Despite this statement, there is no communicated plan in place to make their drug accessible both in terms of production and cost to patients by the time it's removed. **Removing Zepbound (tirzepatide) from the shortage list without addressing these issues could leave many patients, including myself, without reliable, affordable access to the medication we need.**

I urge you to advocate for measures that will improve the availability of GLP-1 drugs and support cost-effective alternatives like maintaining access to the compounded version or incentivizing insurance policies to cover obesity treatments. Ensuring consistent access to these drugs is vital for individuals like myself who depend on them for effective obesity management.

Thank you for your attention to this critical issue!

Sincerely,

[YOUR_NAME]
[YOUR_ADDRESS]
[YOUR_EMAIL]

[1]

<https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-ceo-says-weight-loss-drug-shortage-end-very-soon-bloomberg-news-reports-2024-08-01/>